RES Group, Inc Email Formats
Biotechnology Research • 
Needham, Massachusetts, United States • 21-50 Employees
RES Group, Inc Email Formats
RES Group, Inc uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@resgroupinc.com), used 46.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@resgroupinc.com | 46.2% |
{last name}{last name} | doedoe@resgroupinc.com | 30.8% |
{first initial}.{last name} | j.doe@resgroupinc.com | 15.4% |
{first name}{last name} | johndoe@resgroupinc.com | 7.7% |
Key Contact at RES Group, Inc
Glen Ko
Ceo
Company overview
| Headquarters | Needham, Massachusetts, United States |
| Phone number | +13036382533 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Immuno-Oncology Models, Antibody-Drug Conjugates Models, Disease-Progression Models, Fih (First-In-Human) Dosing, Gene Therapy Models, Hematological Toxicity Models, Ind (Investigational New Drug) Support, Lysosomal Disorder Models, Midd (Model Informed Drug Development), Protein Degrader Models |
| Founded | 2003 |
| Employees | 21-50 |
| Socials |
About RES Group, Inc
RES Group Inc, an MIT spin-off and a pioneer in QSP (Quantitative Systems Pharmacology) modeling since 2001, is dedicated to accelerating and de-risking drug development. Utilizing mechanistic QSP modeling, we offer a range of services including First-in-Human (FIH) dose projections for IND applications, toxicity projections for regulatory submissions, and support for early-stage drug development. With a track record of successfully collaborating on over 100 new drug developments, we have earned the trust of biotech and pharmaceutical companies alike, as demonstrated by the following examples: Our MIDD (Model Informed Drug Development) approach for Takeda’s application for ultra-rare blood clotting disorder was recently approved by FDA: November 9, 2023 Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP). Our human dose projection was recently accepted in the IND clearance in treating Duchenne muscular dystrophy: November 14, 2023 Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
RES Group, Inc has 7 employees across 3 departments.
Departments
Number of employees
Funding Data
RES Group, Inc has never raised funding before.
RES Group, Inc Tech Stack
Discover the technologies and tools that power RES Group, Inc's digital infrastructure, from frameworks to analytics platforms.
Font scripts
JavaScript libraries
JavaScript libraries
Security
Ecommerce
Hosting
Miscellaneous
Security
JavaScript libraries
JavaScript libraries
JavaScript libraries
Netherlands
Switzerland
AustraliaFrequently asked questions
4.8
40,000 users
